摘要
目的观察肝纤康对CCl4诱导的大鼠肝纤维化的影响并探讨其可能机制。方法用CCl4复制大鼠肝纤维化模型,同时予以肝纤康灌胃治疗,测定血清ALT、MDA、HA、LM及肝组织GSH、Hyp含量,并观察肝组织病理变化。结果模型组血清ALT、MDA、HA、LM及肝组织Hyp含量显著升高,肝组织GSH含量显著降低,肝纤维化病变明显;肝纤康治疗组血清ALT、MDA、HA、LM及肝组织Hyp含量明显降低,肝组织GSH含量明显升高,肝纤维化病变明显减轻。结论肝纤康对大鼠肝纤维化具有明显抑制作用,其机制可能与减轻肝细胞脂质过氧化损伤,减少细胞外基质在肝组织沉积有关。
Objective To study the inhibitory effect of Ganxiankang decoction on hepatic fibrosis induced by CCl4 in rats. Methods Liver fibrosis in rats was induced by subcutaneous injection of CCl4 and Ganxiankang decoction was administered by intragastric injection. The serum levels of alanine aminotransferase （ALT） , malondialdehyde （ MDA）, hyaluronic acid （ HA ）, laminin （LM） and hydroxyproline （ Hyp ）, GSH in liver tissue were determined. And the pathogenic changes of liver tissue were also observed. Results In model group, the serum levels of ALT, MDA, HA, LM and Hyp in liver tissue were significantly increased, while liver content of GSH was markedly reduced and liver fibrosis was obviously observed. After treated Ganxiankang decoction supplemented rats, the serum levels of ALT, MDA, HA, LM and Hyp were significantly reduced, and liver content of GSH was markedly restored. Liver fibrosis was evidently attenuated. Conclusion Ganxiankang decoction was capable of attenuating liver fibrosis in rats, which might be derived from the inhibition of lipid peroxidation.
出处
《现代中药研究与实践》
CAS
2008年第3期29-32,共4页
Research and Practice on Chinese Medicines
关键词
肝纤维化
肝纤康
细胞外基质
羟脯氨酸
liver fibrosis
Ganxiankang decoction
extracellular matrix
hydroxyproline
